Drug Pricing & Negotiation
Expert articles and analysis related to drug pricing & negotiation.
AI Summary — Last 24 Hours
Over the past week, the Trump administration's push for drug pricing reform has become more pronounced, particularly through the ongoing implications of the most-favored nation (MFN) deals with pharmaceutical companies, which are set to expire for some manufacturers. This aligns with President Trump's strategy to compel European countries to shoulder a greater cost of pharmaceuticals, thereby potentially lowering U.S. drug prices but creating uncertainty for international stakeholders. Concurrently, state programs are facing budget constraints, leading to restricted access to essential HIV medications, highlighting the fragility of healthcare financing amidst changing policies and economic pressures, as noted in the situation surrounding the Ryan White HIV/AIDS Program.
Related Articles
Real world experience with insurers pushing back on copay cards
As reported by Kaiser Health News: The value of drugmakers’ copay cards has become more unpredictable as insurers try to restrict their use. Many insurance plans, for instance, do not count the money ...
STAT+: Moderna to pay Roivant up to $2.25 billion to settle patent lawsuit behind mRNA vaccines
A settlement provides a massive windfall for Arbutus and Roivant and avoids a worst-case scenario for Moderna.
STAT+: Virginia lawmakers push a new approach to a prescription drug affordability board
As states try to contain the cost of prescription drugs, Virginia lawmakers are pushing an affordability board they believe will go further than efforts in other states.
Opinion: CMS shouldn’t be paying for higher-than-necessary doses of cancer drugs
In cancer treatment, higher doses with worse side effects often don’t lead to better outcomes.
STAT+: Trump can’t break free from vaccine politics
Trump is trying to shift the focus toward healthy eating and cheaper drugs. But vaccines keeping coming back up.
STAT+: Prime Medicine to seek approval for gene-editing treatment after two-patient trial
Prime Medicine's application will test an FDA that has promised to speed new gene-editing treatments but has recently spurned some.
STAT+: CMS wants more drugmakers to join Medicaid ‘most-favored nations’ pilot
More UniQure drama at the FDA, a new Medicaid pilot program, and other biotech news
STAT+: FDA is ‘not convinced’ UniQure’s Huntington’s therapy has benefit, senior official says
The FDA believes that an experimental therapy for Huntington’s disease from UniQure wasn't providing benefit for patients, a senior official told STAT.
STAT+: Pharmalittle: We’re reading about an FDA-UniQure feud, Pfizer’s ‘problem’ with the agency, and more
The FDA concluded that UniQure's experimental Huntington’s treatment was not providing benefit for patients based on existing clinical data
Analyzing Changes in Medicare Part D Enrollment for 2026
The Medicare Part D prescription drug benefit is provided by private plans, either Medicare Advantage plans that offer drug coverage (MA-PDs) or, for those in traditional Medicare, stand-alone prescri...